Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4249 trials
Conditions PRE-HYPERTENSION
Phase NA
Enrollment 45
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

Pre-hypertension is defined as systolic blood pressure between 120-139mmHg or diastolic blood pressure between 80-89mmHg and is considered a risk factor for developing hypertension. Early lifestyle interventions such as aerobic exercise and breathing techniques may help prevent progression to hypertension. This randomised controlled trial aims to determine the additional effects of pilates breathing and diaphragmatic breathing combined with moderate-intensity continuous treadmill training on blood pressure, chest expansion, pulmonary function and quality of life in pre-hypertensive patients. A total of 45 participants will be randomly allocated into three groups: treadmill training with pilates breathing, tredmill training with diaphragmtic brething and treadmill training alone. The intervention will be conducted for 6 weeks. Outcome measures including blood pressure, pulmonary function, chest expansion and quality of life will be assesed before and after the intervention.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: Treadmill Training (Moderate-intensity continuous training) — 70% of maximum heart rate for 20-35 minutes, three sessions per week for six weeks.
  • Other: Pilates Breathing — Controlled lateral breathing technique focusing on rib cage expansion and core activation performed for 10-15 minutes, with low intensity, the perceived effort should be 3-4/10, with 3 days/week. A 06 weeks protocol will be followed. Steps: Patient in neutral spine position and hands placed on rib cage and abdomen. Inhale deeply expanding the ribs laterally. Exhale drawing the navel inward to engage core muscles.
  • Other: Diaphragmatic Breathing — Slow deep breathing emphasizing diaphragmatic movement performed for 10-15 minutes, with low intensity, the perceived effort should be 3-4/10, with 3 days/week. A 06 weeks protocol will be followed. Steps: Patient in supine or in seated position. Place one hand on chest and one below the ribs. Inhale slowly through the nose expanding the abdomen. Exhale through pursed lips, allowing the abdomen to fall inward and chest should remain still.

Primary Outcomes

  • Blood Pressure (SBP and DBP) (06 weeks)
  • Chest Expansion (06 weeks)
  • Pulmonary Function Test (06 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-02-28
Completion: 2026-05-15
Eligibility
Age: 20 Years and older
Sex: ALL
Volunteers: false
Enrollment: 45 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Foundation University Islamabad
Contact Information
Study Contact:
Iqra Zahid, MSPT-CPT
03310174987
iqrazahid31801@gmail.com
Sana Bashir, PhD*
+923218529475
drsana.bashir@fui.edu.pk
Sana Bashir
03218529475
drsana.bashir@fui.edu.pk
Foundation University Islamabad
Interventions
  • Other: Treadmill Training (Moderate-intensity continuous training) — 70% of maximum heart rate for 20-35 minutes, three sessions per week for six weeks.
  • Other: Pilates Breathing — Controlled lateral breathing technique focusing on rib cage expansion and core activation performed for 10-15 minutes, with low intensity, the perceived effort should be 3-4/10, with 3 days/week. A 06 weeks protocol will be followed. Steps: Patient in neutral spine position and hands placed on rib cage and abdomen. Inhale deeply expanding the ribs laterally. Exhale drawing the navel inward to engage core muscles.
  • Other: Diaphragmatic Breathing — Slow deep breathing emphasizing diaphragmatic movement performed for 10-15 minutes, with low intensity, the perceived effort should be 3-4/10, with 3 days/week. A 06 weeks protocol will be followed. Steps: Patient in supine or in seated position. Place one hand on chest and one below the ribs. Inhale slowly through the nose expanding the abdomen. Exhale through pursed lips, allowing the abdomen to fall inward and chest should remain still.
Study Locations (1 sites)
Foundation University Islamabad, Islamabad, Pakistan
Eligibility Criteria
Inclusion Criteria: * Prehypertensive individuals (SBP 120-139 mmHg or DBP 80-89 mmHg) * Age 20-55 years * Both male and female * Sedentary individuals according to IPAQ * Willing to participate and provide informed consent Exclusion Criteria: * Diagnosed hypertension (≥140/90 mmHg) * Cardiopulmonary diseases (COPD, asthma, CAD, heart failure) * Musculoskeletal conditions preventing exercise * Neurological disorders * Pregnancy * Participation in structured exercise in last 3 months
Conditions Stroke, Brain Ischemia, Cerebral Hemorrh...
Phase NA
Enrollment 2510
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

This cluster randomized controlled trial aims to evaluate the effectiveness of a novel telemedicine-enabled integrated care model led by rural doctors in reducing cardiovascular and cerebrovascular events among elderly adults (≥65 years) at high risk of stroke in rural China. A total of 39 village clinics will be randomized to either the intervention group (digital health platform-supported integrated care) or the control group (enhanced usual care). The primary outcome is a composite of cardiovascular death, stroke, and hospitalization for heart failure or acute coronary syndrome at 36 months.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Enhanced Usual Stroke Care — Rural doctors provide monthly face-to-face care based on national guidelines, including symptom monitoring, blood pressure measurement, medication guidance, and patient education. Referrals to tertiary hospitals are made through conventional channels.
  • Behavioral: Digital Health Platform-Supported Integrated Stroke Management — Patient electronic health record management AI-powered clinical decision support for medication adjustment based on Chinese stroke guidelines Weekly remote video consultation with neurologists from tertiary hospitals Automated follow-up and medication adherence reminders Structured education and training for both rural doctors and patients

Primary Outcomes

  • Composite of Cardiovascular Death, Stroke, and Hospitalization for Heart Failure or Acute Coronary Syndrome at 36 Months (36 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-06-01
Completion: 2030-06-30
Eligibility
Age: 65 Years and older
Sex: ALL
Volunteers: false
Enrollment: 2510 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Jiangsu Province (Suqian) Hospital
Contact Information
Study Contact:
Liu Qianghui Director of Suqian Hospital, Jiangsu Provincial People's Hospi
15951598055
jasonlion815@163.com
Zhao Jinxiang
15862826785
zhaojinxiang_ntu@163.com
Jiangsu Province (Suqian)Hospital
Zhao Jinxiang
15862826785
zhaojinxiang_ntu@163.com
Suqian Hospital Affiliated to Jiangsu Provincial People's Hospital
Interventions
  • Behavioral: Enhanced Usual Stroke Care — Rural doctors provide monthly face-to-face care based on national guidelines, including symptom monitoring, blood pressure measurement, medication guidance, and patient education. Referrals to tertiary hospitals are made through conventional channels.
  • Behavioral: Digital Health Platform-Supported Integrated Stroke Management — Patient electronic health record management AI-powered clinical decision support for medication adjustment based on Chinese stroke guidelines Weekly remote video consultation with neurologists from tertiary hospitals Automated follow-up and medication adherence reminders Structured education and training for both rural doctors and patients
Study Locations (2 sites)
Jiangsu Province (Suqian)Hospital, Suqian, Jiangsu China
Suqian Hospital Affiliated to Jiangsu Provincial People's Hospital, Suqian, Jiangsu China
Eligibility Criteria
Inclusion Criteria: 1. Aged 65 years or older 2. Rural residents with household registration or long-term residence (≥6 months/year) in the study area 3. High risk of stroke as defined by the National Health Commission's "8+2" stroke risk screening tool: ≥3 risk factors OR history of stroke/TIA 4. Willing to receive long-term health management from the assigned village clinic 5. Written informed consent provided by the participant or their legal representative Exclusion Criteria: 1. Severe dementia or psychiatric disorder that prevents completion of study follow-up and assessments 2. Life expectancy less than 1 year (e.g., advanced malignancy, end-stage renal disease) 3. Currently participating in another interventional clinical trial
Conditions Elevated Blood Pressure, Vascular Health...
Phase NA
Enrollment 32
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

This research aims to develop an evidence-based classification for sodium-rich condiments (natremic index) based on their CVD-related risks. It is hypothesised that the acute cardiovascular and physiological response (effectively extrapolated to long-term CVD risks) to meals prepared with various sodium-rich condiments can be leveraged upon for the development of such an index that will systematically classify sodium-rich condiments based on the risk they present to cardiovascular health.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Other Masking/blinding: Double

Interventions / Regimen

  • Other: Control porridge with no condiments — To examine acute cardiovascular health response to plain porridge.
  • Other: Porridge with light soya sauce — To examine acute cardiovascular health response to plain porridge with saltiness-matched light soya sauce
  • Other: Porridge with fermented bean paste — To examine acute cardiovascular health response to plain porridge with saltiness-matched fermented bean paste
  • Other: Porridge with table salt — To examine acute cardiovascular health response to plain porridge with saltiness-matched table salt.

Primary Outcomes

  • Endopat assessment (EndoPAT assessments which will serve as the primary outcome of interest will be measured at postprandial intervals (up to 3 measurements) over 4 hours.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-22
Completion: 2026-09-22
Eligibility
Age: 50 Years and older
Sex: ALL
Volunteers: true
Enrollment: 32 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Singapore Institute of Food and Biotechnology Innovation
Contact Information
Study Contact:
Darel Toh, PhD
64074149
darel_toh@a-star.edu.sg
Bhupinder Kaur, MSc
64074355
bhupinder_kaur@a-star.edu.sg
Darel Toh Wee Kiat, PhD
darel_toh@a-star.edu.sg
Clinical Nutrition Research Centre
Interventions
  • Other: Control porridge with no condiments — To examine acute cardiovascular health response to plain porridge.
  • Other: Porridge with light soya sauce — To examine acute cardiovascular health response to plain porridge with saltiness-matched light soya sauce
  • Other: Porridge with fermented bean paste — To examine acute cardiovascular health response to plain porridge with saltiness-matched fermented bean paste
  • Other: Porridge with table salt — To examine acute cardiovascular health response to plain porridge with saltiness-matched table salt.
Study Locations (1 sites)
Clinical Nutrition Research Centre, Singapore, 117599 Singapore
Eligibility Criteria
Inclusion Criteria: 1. ≥ 50, \< 75 years old 2. Male or postmenopausal female (self-reported) 3. ≥ 50 kg body weight 4. Systolic blood pressure (≥ 130, \< 160 mmHg) or diastolic blood pressure (≥ 85, \< 100 mmHg) 5. Willing and able to follow intervention protocol 6. Ability to identify basic tastes (determined by taste discrimination test) 7. English speaking Exclusion Criteria: 1. Prescribed and taking medication which may affect study outcomes (i.e. for blood pressure management, blood thinning etc.) in consultation with study physician (Prof Melvin Leow) and PI(Dr Darel Toh) 2. Type 1 or type 2 diabetes mellitus (i.e. fasting blood glucose ≥ 7.0 mmol/L or HbA1c ≥ 6.5 %) 3. Taking dietary supplements which may affect study outcomes one month prior to their first visit in consultation with study physician, PI and study team 4. Obesity (BMI ≥ 27.5 kg/m2) 5. History or known present diagnosis of hematological (G6PD and coagulation disorders), hepatic (hepatitis B and C), renal, gastrointestional or other relevant disease / disorders which may affect the outcomes of interest in consultation with study physician, PI and study team 6. History of arteriovenous shunt or mastectomy 7. Women who are pregnant, lactating or planning pregnancy 8. History or present diagnosis of HIV and/or tuberculosis 9. History of severe vasovagal syncope (blackouts or near faints) following blood draw 10. Drug abuse within last 5 years 11. Excessive alcoholic beverage consumption \> 2 servings per day (1 serving defined as 360 mL beer, 150 mL wine or 45 mL distilled spirits) 12. Smoking (cigarette, e-cigarette, cigar, pipe, vape) 13. Engaging in habitual vigorous physical activity (as defined by physical activity questionnaire-PAR) 14. Allergic or intolerance to intervention foods. 15. Dislike or unwilling to consume intervention foods 16. Photophobic (sensitivity to intense lights and colours), particularly to intense red lights 17. Has sinus problems problems that affect taste and smell 18. Involvement in other clinical studies that may influence the outcome of the study 19. An ASTAR Staff. 20. A study team member or their immediate family member
Conditions Normal Tension Glaucoma, Cataract
Phase NA
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to assess whether endoscopic cyclophotocoagulation added to cataract surgery lowers intraocular pressure more than cataract surgery alone in patients with normal tension glaucoma.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Phaco — phacoemulsification of cataract only
  • Procedure: Phaco+ECP — Endoscopic cyclophotocoagulation is done in the same procedure as phacoemulsification of cataract

Primary Outcomes

  • Succes rate (One year postoperatively)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2020-12-08
Completion: 2026-12-01
Eligibility
Age: 55 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Helsinki University Central Hospital
Principal Investigators:
  • Mika Harju, MD, PhD (PRINCIPAL_INVESTIGATOR) - Helsinki University Central Hospital
Contact Information
Study Contact:
Nina M Lindbohm, MD, PhD
+358505715668
nina.lindbohm@hus.fi
Jukka AO Moilanen, MD, PhD
+358405820860
jukka.moilanen@hus.fi
Helsinki University Hospital
Interventions
  • Procedure: Phaco — phacoemulsification of cataract only
  • Procedure: Phaco+ECP — Endoscopic cyclophotocoagulation is done in the same procedure as phacoemulsification of cataract
Study Locations (1 sites)
Helsinki University Hospital, Helsinki, 00029 Finland
Eligibility Criteria
Inclusion Criteria: * Signed Informed Consent * Normal Tension Glaucoma with typical nerve fiber layer defects in red-free photographs and/or optical coherence tomography (OCT) and possible equivalent visual field defects, IOP never more than 21 mmHg, and open anterior chamber angle * Glaucoma stable with current medication assessed by a glaucoma specialist * Clinically significant cataract Exclusion Criteria: * Secondary Glaucoma e.g. due to previous injury or uveitis * Exfoliation syndrome * Pigment dispersion syndrome * Previous transscleral or endoscopic cyclophotocoagulation * Previous other glaucoma surgery * Cataract due to eye injury or congenital cataract * Zonular weakness due to Marfan syndrome or other * Previous retinal detachment * Previous intraocular surgery like vitrectomy and other retinal surgery * Wet age-related macular degeneration * Diabetic retonopathy * Previous corneal transplant or previous refractive surgery * Fuchs' dystrophy and other abnormalities compromising corneal clarity like scars * The patient does not want to participate in the study * The glaucoma progresses on current IOP * The patient does not speak Finnish, Swedish or English * Dementia * Only eye with vision worse than 20/200 or loss of central visual field
Conditions High Blood Pressure
Phase NA
Enrollment 60
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

This project aims to address healthcare disparities among Navaho people diagnosed with hypertension or prehypertension through three main objectives. Firstly, it identifies and shares insights on healthcare access disparities affecting Navaho individuals experiencing nonadherence to hypertension treatment. Secondly, the proposal develops a telehealth solution based on factors identified as knowledge gaps caused by healthcare access disparities in hypertension management; we will use the factors to design a series of engaging minigames that can be incorporated into the larger CardioCare Quest. These minigames will be co-designed with end users and clinicians. Finally, the proposal conducts comprehensive qualitative and quantitative assessments of user experiences, perceptions, and challenges with CardioCare Quest.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: CardioCare Quest — CardioCare Quest will be the first telehealth game designed to enhance High Blood Pressure (HBP) treatment compliance and education about HBP, featuring a telemetry system that provides physicians and researchers data about sustainable healthy heart lifestyles beyond the clinic. The novelty of CardioCare Quest lies in its ability to compel HBP patients to playfully celebrate the mundane everyday practices that lead to sustainable habits and improved health outcomes using culturally sensitive and community-based design practices.

Primary Outcomes

  • Indigenous ways of knowing hypertension, measured by patient activity workbook using emoji stickers (Baseline, 6 months)
  • Indigenous ways of knowing hypertension, measured by Motivation, Engagement, & Thriving in User Experience (METUX) Scale (Baseline, 6 months)
  • Change from baseline in Participants' experience score after the design of minigames artifacts integrated into CardioCare Quest on the METUX scales (Time Frame: Baseline, 7 months)
  • Quantifying Hypertension Medication Adherence Among People Using Telemetry Data from CardioCare Quest (Time Frame: End of study, up to 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-06-30
Completion: 2026-11-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Northern Arizona University
Collaborators: National Institute on Minority Health and Health Disparities (NIMHD)
Principal Investigators:
  • Tochukwu Ikwunne, PhD (PRINCIPAL_INVESTIGATOR) - Northern Arizona University
Contact Information
Study Contact:
Tochukwu Ikwunne, PhD
9282668389
tochukwu.ikwunne@nau.edu
Jared Duval, PhD
7744523372
jared.duval@nau.edu
Jared S Duval, PhD
928-523-0429
jared.duval@nau.edu
School of Informatics Computing and Cyber Systems
Interventions
  • Behavioral: CardioCare Quest — CardioCare Quest will be the first telehealth game designed to enhance High Blood Pressure (HBP) treatment compliance and education about HBP, featuring a telemetry system that provides physicians and researchers data about sustainable healthy heart lifestyles beyond the clinic. The novelty of CardioCare Quest lies in its ability to compel HBP patients to playfully celebrate the mundane everyday practices that lead to sustainable habits and improved health outcomes using culturally sensitive and community-based design practices.
Study Locations (2 sites)
School of Informatics Computing and Cyber Systems, Flagstaff, Arizona 86001 United States
Northern Arizona University, Flagstaff, Arizona 86005 United States
Eligibility Criteria
Inclusion Criteria: * We are interested in interviewing people who receive, give, or are affected by HBP therapy. This includes medical professionals, patients with HBP between the ages of 18 and above, their family members, caretakers, and relevant community professionals such as social workers. * The project targets Urban Indigenous individuals in the patient category. A potential participant will be recognized as Urban Indigenous upon completing the registration form provided to them. * The project is interested in Navajo Nation groups that reside in Flagstaff. Exclusion Criteria: * Patients with uncontrolled or severely severe hypertension will be excluded from this study since controlling these instances may be the primary emphasis of the study rather than its intervention. * The exclusion will be based on considerations such as the severity of hypertension, the potential risks associated with uncontrolled hypertension, and the overall health status of the patient. * Participants having specific medical conditions that could interfere with or pose risks to the study's outcomes (e.g., severe heart disease, advanced kidney disease) will be excluded. * Pregnant women or those who want to get pregnant during the study period will be excluded due to the potential dangers to both the pregnant woman and the fetus.
Conditions Hypertension, Menopause, Premature, Meno...
Phase Not Applicable
Enrollment 160
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

This is a cross-sectional study in which the investigators will determine the impact of premature/early menopause on MSNA, BP and baroreflex sensitivity in younger (≤49 yr old) and older (≥50 yr old) women. Specifically, aim one will determine mechanisms driving autonomic dysregulation of BP in premature and early menopausal women and aim two will determine mechanisms driving autonomic dysregulation of BP in older menopausal women. The study design outlined below will permit testing of aim one and aim two.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: Microneurography to measure muscle sympathetic nerve activity (MSNA) — Microneurography is a direct measurement of electrical activity of peripheral sympathetic nerves
  • Diagnostic Test: Baroreflex sensitivity testing — Two arms of the baroreflex that will be tested in this study are sympathetic and cardiovagal. Static baroreflex is tested during baseline resting conditions and dynamic baroreflex is tested during Valsalva maneuvers.
  • Diagnostic Test: Sympathoexcitatory Maneuvers — Cold Pressor Test (CPT) and Upper extremity fatiguing contraction with post exercise circulatory occlusion (PECO) will be performed
  • Diagnostic Test: Blood tests — Serum FSH, estrogen, progesterone, and testosterone will be measured

Primary Outcomes

  • Muscle Sympathetic Nerve Activity (MSNA) (bursts per minute) (3 hours)
  • Muscle Sympathetic Nerve Activity (MSNA) (bursts/100 heart beats) (3 hours)
  • Cardiac baroreflex sensitivity (3 hours)
  • Sympathetic baroreflex sensitivity (3 hours)
  • Systolic Blood Pressure (mmHg) (3 hours)
  • Diastolic Blood Pressure (mmHg) (3 hours)
  • Mean Arterial Blood Pressure (mmHg) (3 hours)
  • Heart Rate (beats/min) (3 hours)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2019-10-01
Completion: 2026-12-30
Eligibility
Age: 35 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 160 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Minnesota
Contact Information
Study Contact:
Manda Keller-Ross, PhD, DPT, PT
612-625-3175
kell0529@umn.edu
Manda Keller-Ross, PhD, DPT, PT
612-625-3175
kell0529@umn.edu
University of Minnesota
Interventions
  • Diagnostic Test: Microneurography to measure muscle sympathetic nerve activity (MSNA) — Microneurography is a direct measurement of electrical activity of peripheral sympathetic nerves
  • Diagnostic Test: Baroreflex sensitivity testing — Two arms of the baroreflex that will be tested in this study are sympathetic and cardiovagal. Static baroreflex is tested during baseline resting conditions and dynamic baroreflex is tested during Valsalva maneuvers.
  • Diagnostic Test: Sympathoexcitatory Maneuvers — Cold Pressor Test (CPT) and Upper extremity fatiguing contraction with post exercise circulatory occlusion (PECO) will be performed
  • Diagnostic Test: Blood tests — Serum FSH, estrogen, progesterone, and testosterone will be measured
Study Locations (1 sites)
University of Minnesota, Minneapolis, Minnesota 55455 United States
Eligibility Criteria
Inclusion Criteria: * Aged 35-49 or 50-70 years of age who experienced premature (\<40) or early (≤45) menopause * Premenopausal 35-49 years of age * Typical-age menopause (i.e., after 45 years of age), who are between 50-70 years old * Menopause will be confirmed by subject report of amenorrhea for 12 months and serum FSH of \>30 mIU/mL Exclusion Criteria: * Current nicotine/tobacco use within the past six months * Are diabetic or asthmatic * Have diagnosed significant carotid stenosis * Have a history of significant autonomic dysfunction, heart disease, respiratory disease or a severe neurologic condition such as stroke or traumatic brain injury. * Have existing metabolic or endocrine abnormities * Take any heart/blood pressure medications that are determined to interfere with study outcomes * IF the participant is premenopausal AND currently taking OC or other exogenous steroids that are determined to interfere with study outcomes * Females who classify as having early or premature menopause AND are not willing to discontinue OC or MHT in order to complete the study * Are pregnant or breastfeeding
Conditions Pulmonary Arterial Hypertension (PAH), P...
Phase PHASE2
Enrollment 40
Locations 23 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

This study evaluates the effect of ROC-101 in adults with either Pulmonary Arterial Hypertension (PAH) or Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD-PH). Each eligible participant will receive standard of care (SOC) plus ROC-101 for a 24-week treatment period, followed by a long-term extension period of the study through the end of the program or marketing approval/authorization.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: ROC-101 — Oral, daily administered Rho kinase inhibitor

Primary Outcomes

  • Change in Pulmonary Vascular Resistance (PVR) from Baseline versus at 24 weeks (Baseline and 24 weeks)
  • Safety assessments: Number of Participants Who Experienced an Adverse Event (AE) (24 Weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-10-01
Completion: 2029-03
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: AllRock Bio, Inc.
Contact Information
Study Contact:
Arizona Pulmonary Specialist
857-239-1966
info@allrockbio.com
Arizona Pulmonary Specialists
University of California Davis Health
857-239-1966
info@allrockbio.com
University of California Davis Health
University of Colorado
857-239-1966
info@allrockbio.com
University of Colorado
Interventions
  • Drug: ROC-101 — Oral, daily administered Rho kinase inhibitor
Study Locations (23 sites)
Arizona Pulmonary Specialists, Phoenix, Arizona 85012 United States
University of California Davis Health, Rancho Cordova, California 95670 United States
University of Colorado, Aurora, Colorado 80045 United States
George Washington University Medical, Washington D.C., District of Columbia 20037 United States
Mayo Clinic of Florida, Jacksonville, Florida 32224 United States
The University of Kansas Medical Center Research Institute, Kansas City, Kansas 66160 United States
University of Michigan, Ann Arbor, Michigan 48109 United States
Ohio State University, Columbus, Ohio 43210 United States
Bend Memorial Clinic, Bend, Oregon 97701 United States
Temple University, Philadelphia, Pennsylvania 19140 United States
Eligibility Criteria
Key Inclusion Criteria: 1. Must be age 18 or older at the time of signing the informed consent form (ICF). The participant must understand and voluntarily sign an ICF prior to any study-related procedures 2. Documented findings on a right heart catheterization (RHC) consistent with a diagnosis World Health Organization (WHO) Group 1 PAH or WHO GROUP 3 PAH 3. Symptomatic Pulmonary Hypertension (PH) classified as WHO Functional Class II or III symptoms 4. PAH participants: Pulmonary Vascular Resistance (PVR) of ≥ 5 Wood units (≥ 400 dynes/sec/cm-5) and, Pulmonary Capillary Wedge Pressure (PCWP) ≤ 15 mmHg and Mean Pulmonary Arterial Pressure (mPAP) \> 20 mm Hg and ILD-PH participants: PVR of ≥ 3 Wood units (≥ 240 dynes/sec/cm-5) with a maximum enrollment of 5 participants with PVR between 3 and 4 Wood units inclusive (240-320 dynes/sec/cm-5 inclusive) and the remaining 5 participants must have PVR \>4 Wood units (\> 320 dynes/sec/cm-5) and, PCWP ≤ 15 mmHg and mPAP \> 20 mm Hg 5. Participants on stable background therapy for PAH or ILD-PH. 6. Females of childbearing potential (as defined in protocol) must agree to use highly effective contraception (as defined in the protocol) 7. Male participants must follow protocol-specified contraception guidance. 8. Participants must be able to communicate well with Investigators, understand the study procedures in the ICF and are agreeable to complete the study in accordance with the protocol. 9. Must be able to swallow tablets. 10. Pulmonary function tests (PFT): PAH participants at Screening as follows: 1. Forced Vital Capacity (FVC) \> 70% predicted; or if between 60% to 70% predicted, or if not possible to be determined, confirmatory High-Resolution Computed Tomography (HRCT) indicating no more than mild (\<10% fibrosis) ILD and emphysema (less than 10%); and 2. The ratio of FEV1 (first second)/FVC \> 0.70 of predicted. ILD-PH participants at Screening as follows: 1. PFTs consistent with their ILD diagnosis and showing FEV1/ FVC ratio \> 65% and HRCT having more than 10% fibrosis and less than 10% emphysema, based on the proportion of lung parenchyma affected by fibrotic and emphysema changes. and, 2. Minimum FVC of 50% and diffusing capacity for carbon monoxide (DLCO) (corrected for Hb g/dl) \>25% 11. In PAH participants, i.e., Cohorts 1 and 2 only, ventilation-perfusion (VQ) scan (or, if unavailable, a negative Computed tomography pulmonary angiogram \[CTPA\] or pulmonary angiography result), any time prior to Screening or conducted during the Screening Period, with a normal or low probability result that is not clinically significant 12. Acceptable Electrocardiogram (ECG) findings as assessed by the Investigator or qualified designee at the Screening Visit and at the Baseline Visit (Day 1), including each criterion as listed below: * Normal sinus rhythm (HR) between 40 and 100 beats per minute, inclusive); * Corrected QT Interval (QTcF) interval ≤ 450 msec (males) and ≤ 460 msec (females); * QRS interval ≤ 120 msec; if \> 120 msec, result will be confirmed by a manual overread 13. Body weight at the Screening visit and at Baseline (Day 1) is greater than 50.0 kg and the body mass index (BMI) is in the range of 19.00 to 36.00 kg/m2, inclusive 14. 6MWD ≥ 100 and ≤ 550 meters repeated twice, once during Screening Period and once at the Baseline Visit (Day 1) and both values within 15% of each other, allowing for a third repeat if \> 15% difference, calculated from the higher/highest value Key Exclusion Criteria: 1. Diagnosis of PH WHO Groups 2, 4, or 5 2. Diagnosis of the following PAH Group 1 subtypes: human immunodeficiency virus (HIV)-associated PAH, PAH associated with portal hypertension, schistosomiasis-associated PAH and pulmonary veno-occlusive disease and/or pulmonary capillary hemangiomatosis 3. Positive blood test for hepatitis B virus surface antigen (HBsAg), hepatitis C virus (HCV) antibody (HCVAb) (unless participants have had treatment for HCV and have a negative HCV ribonucleic acid \[RNA\] polymerase chain reaction \[PCR\]) or HIV antibody 4. Participants with known hypersensitivity to ROC-101 or any components of its formulations 5. History of malignancy within the last 5 years, with the exception of fully excised or treated basal cell carcinoma, cervical carcinoma in-situ, or ≤ 2 squamous cell carcinomas of the skin 6. History of clinically significant (as determined by the Investigator) non-PAH related cardiac, endocrine, hematologic, hepatic, immune, metabolic, urologic, pulmonary, neurologic, neuromuscular, dermatologic, psychiatric, renal, and/or other diseases that may limit participation in the study 7. Participation in another clinical trial involving intervention with another investigational drug, approved therapy for investigational use, or investigational device within 4 weeks prior to Baseline Visit (unless it is in the follow-up period of an interventional study), or if the half-life of the previous product is known, within 5× the half-life prior to Baseline Visit (Day 1), whichever is longer 8. Major surgery within 8 weeks prior to Baseline Visit (Day 1) or major surgery scheduled or planned in the main study. Participants must have completely recovered from any previous surgery prior to the Screening Visit 9. Prior heart or heart-lung transplants, or a participant listed for heart and/or lung transplantation or prior pneumonectomy 10. Pregnant or breastfeeding females 11. Males who do not agree to protocol contraception guidelines 12. Uncontrolled systemic hypertension as evidenced by sitting SBP \> 160 mm Hg or sitting diastolic BP \> 100 mm Hg during Screening Visit and Baseline Visit (Day 1) after a period of rest 13. Systolic BP \< 90 mm Hg during Screening Visit or at Baseline Visit (Day 1) or, if during screening, orthostatic systolic BP decreases by more than 20 mm Hg and the participant is symptomatic. 14. History of known pericardial constriction or a clinically significant (more than trace or trivial \[i.e., ≥10 mm\]) pericardial effusion seen in diastole or in both systole and diastole on echocardiogram (ECHO) historically and confirmed on screening ECHO 15. RHC contraindicated during the study per Investigator 16. Cerebrovascular accident within 3 months (120 days) of start of Screening 17. History of restrictive or constrictive or congestive cardiomyopathy 18. Left ventricular ejection fraction (LVEF) \< 50% on historical echocardiogram (ECHO) performed within 6 months prior to start of Screening period (and confirmed during the Screening ECHO) or grade 2 or higher diastolic dysfunction 19. Any current symptomatic coronary disease (myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft surgery, or cardiac anginal chest pain in the past 6 months (180 days) prior to start of Screening) 20. History of acutely decompensated left heart failure or right heart failure within 90 days prior to Baseline, as per Investigator assessment 21. Significant (≥ 2+ \[or \> mild\] regurgitation) mitral regurgitation or aortic regurgitation valvular disease, or more than mild mitral stenosis or aortic stenosis valvular disease as seen on Screening ECHO 22. Started or stopped receiving any general supportive therapy for PH (e.g., oxygen, anticoagulants, digoxin) within 30 days prior to start of Screening 23. Use of supplemental oxygen \> 10 liters/minute or and SpO2 \< 90% while receiving typical oxygen supplementation, unless living at \> 1000 meters altitude above sea level in which SpO2 cannot be lower than 85% while receiving typical oxygen supplementation 24. Received intravenous (IV) inotropes (e.g., dobutamine, dopamine, norepinephrine, vasopressin) within 30 days prior to start of Screening 25. History of atrial septostomy within 180 days prior to start of Screening 26. History of portal hypertension or chronic liver disease, defined as mild to severe hepatic impairment (Child-Pugh Classes A to C
Conditions Apnea, Obstructive
Phase PHASE2
Enrollment 24
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

Obstructive sleep apnea syndrome (OSAS) is associated with hyperaldosteronism with elevated plasma aldosterone/renin ratio, the physiopathological mechanism of which remains uncertain. This hyperaldosteronism contributes to the development of arterial hypertension and cardiovascular complications observed in patients with OSA, in particular by increasing arterial stiffness and heart rate variability. The frequent association of OSA with obesity with metabolic syndrome suggests that excess weight could be responsible for stimulation of aldosterone secretion independent of the renin/angiotensin system. Several studies indicate in particular that the production of mineralocorticoids by the adrenals could be activated by various adipocyte secretion products such as leptin and certain fatty acids after oxidation in the liver. In addition, a recent study showed that basal aldosterone secretion is also controlled by substance P released within the adrenal tissue itself by nerve fibers belonging to the splanchnic contingent. Thus, the oral administration of aprepitant, an antagonist of the substance P receptor (NK1 receptor), to healthy volunteers induces a reduction of approximately 30% in the overall secretion of aldosterone assessed by measuring aldosteronemia and 24-hour aldosteronuria. To the extent that OSA causes sympathetic hypertonia, the hypothesis is that the associated hyperaldosteronism could result from activation of the nervous control of aldosterone secretion, involving substance P and the NK1 receptor. If this is indeed the case, the administration of aprepitant to patients with OSA should result in a significant reduction in aldosteronemia.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Drug: Aprepitant 125 and 80Mg Oral Capsule — Aprepitant 1 oral capsule time a day for 4 days (First day: 125 mg and the 3 last days: 80 mg)
  • Drug: Placebo — Placebo:1 oral capsule time a day for 4 days

Primary Outcomes

  • Rate of aldosterone secretion (Immediately after the intervention/procedure/surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-03-05
Completion: 2027-06-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 24 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital, Rouen
Contact Information
Study Contact:
Antoine-Guy Lopez
02 32 88 90 81
Antoine-Guy.Lopez@chu-rouen.fr
Nell Marty
02 32 88 82 65
nell.marty@chu-rouen.fr
Antoine-Guy Lopez
Antoine-Guy.Lopez@chu-rouen.fr
Antoine-Guy.Lopez@chu-rouen.fr
CHU de Rouen
Interventions
  • Drug: Aprepitant 125 and 80Mg Oral Capsule — Aprepitant 1 oral capsule time a day for 4 days (First day: 125 mg and the 3 last days: 80 mg)
  • Drug: Placebo — Placebo:1 oral capsule time a day for 4 days
Study Locations (1 sites)
CHU de Rouen, Rouen, France 76000 France
Eligibility Criteria
Inclusion Criteria: 1. Subject with severe obstructive sleep apnea syndrome (OSAS) defined by an apnea and hypopnea index (AHI) ≥ 30/h on polysomnography or ventilatory polygraphy (requiring continuous positive airway pressure). 2. Subject with essential hypertension treated medically or by lifestyle and dietary measures or newly diagnosed (defined by SBP ≥ 140 and/or DBP ≥ 90 mmHg according to current SFHTA-HAS recommendations). 3. Patient's agreement to replace diuretics with another neutral antihypertensive treatment (which does not interfere with the renin-angiotensin system), to stop consuming licorice and its derivatives, 7 to 10 days before taking the treatment. experimental and throughout the study (if applicable) Exclusion Criteria: 1. Minor subject or subject aged over 75 years 2. Criteria relating to associated pathologies leading to particular risks: * Subject presenting excessive daytime sleepiness with contraindication to driving (Epworth score \> 16) * Uncontrolled severe cardiovascular disease: myocardial infarction or stroke in the last 6 months, unstable angina, significant valvular heart disease, heart failure (≥ class II of the NYHA classification), uncontrolled cardiac arrhythmia or significant conduction abnormalities. Knowledge of chronic renal insufficiency defined by a glomerular filtration rate \< 60 mL/min/1.73m2 for more than 3 months) or moderate hepatic insufficiency defined by ALT and/or AST transaminases \> 3N) * Epilepsy * Known acute infections linked to HIV, HBV or HCV * Active cancer currently being treated 3. Contraindications to placebo and aprepitant
Conditions Allogeneic Stem Cell Transplantation, Lu...
Phase PHASE3
Enrollment 210
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

Background: Injury or diseases of the heart and lung can sometimes cause scar tissue (fibrosis) to build up in those organs. Current imaging scans can see this scar tissue once it has formed, but researchers want to find a way to detect the fibrosis in its earliest stages, while there might still be time to prevent serious damage. A new tracer (a radioactive substance injected during imaging scans) may be able to help. Objective: To test a new tracer (18F-FAPI-74) during imaging scans in people with heart or lung disease. Eligibility: People aged 18 years and older with lung or heart disease that may cause scarring in those organs. Design: Participants will have 6 clinic visits over 2 years. Participants will be screened: They will have blood tests and tests of their heart and lung function. Those with heart disease will have a magnetic resonance imaging (MRI) scan of the heart. The study tracer will be used with positron emission tomography (PET)/computed tomography (CT) scans. The study tracer will be injected into a vein in the arm. Participants will lie on a padded bed that slides through a donut-shaped machine. Participants will have scans with the study tracer 2 times, 8 to 12 months apart. They will also have standard CT scans and blood tests during these visits. They will also have blood tests at 3 and 6 months between these visits. Participants will have a follow-up visit after 18 to 24 months. The study scans, MRI and standard CT scans, and lung function tests may be repeated....

Design

Study type: Interventional Phases: Phase3 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Drug: [18F]FAPI-74 — Participants will undergo baseline diagnostic 18F-FAPI-74 PET/CT in addition to standard of care imaging (non-contrast chest CT and 18FFDG- PET/CT, cardiac MRI for heart cohort). A follow-up 18F-FAPI- 74 PET/CT with SOC imaging will be performed at 8 to 12 months after the initial scan to assess progression and or the effects of therapies.
  • Diagnostic Test: 18F-FAPI-74 PET/CT Imaging — Fibroblast activation protein-targeted PET detects activated fibroblasts in a range of inflammatory and fibrosing cardiovascular and pulmonary disorders. It is a sensitive and quantifiable intervention to diagnose and monitor the natural history of cardiopulmonary disorders and/or the effects of antifibrotic interventions.

Primary Outcomes

  • To compare 18F-FAPI-74 PET/CT to standard of care imaging (non-contrast chest CT and 18F-FDG-PET/CT, cardiac MRI for heart cohort) to detect fibrosis. (Initial scan, Baseline, 8-12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-09-18
Completion: 2033-05-26
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 210 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigators:
  • Anthony F Suffredini, M.D. (PRINCIPAL_INVESTIGATOR) - National Heart, Lung, and Blood Institute (NHLBI)
Contact Information
Study Contact:
Rosemary McConnell, R.N.
(301) 827-9716
rosemary.mcconnell@nih.gov
Anthony F Suffredini, M.D.
(301) 496-9320
asuffredini@mail.nih.gov
NIH Clinical Center Office of Patient Recruitment (OPR)
800-411-1222
ccopr@nih.gov
National Institutes of Health Clinical Center
Interventions
  • Drug: [18F]FAPI-74 — Participants will undergo baseline diagnostic 18F-FAPI-74 PET/CT in addition to standard of care imaging (non-contrast chest CT and 18FFDG- PET/CT, cardiac MRI for heart cohort). A follow-up 18F-FAPI- 74 PET/CT with SOC imaging will be performed at 8 to 12 months after the initial scan to assess progression and or the effects of therapies.
  • Diagnostic Test: 18F-FAPI-74 PET/CT Imaging — Fibroblast activation protein-targeted PET detects activated fibroblasts in a range of inflammatory and fibrosing cardiovascular and pulmonary disorders. It is a sensitive and quantifiable intervention to diagnose and monitor the natural history of cardiopulmonary disorders and/or the effects of antifibrotic interventions.
Study Locations (1 sites)
National Institutes of Health Clinical Center, Bethesda, Maryland 20892 United States
Eligibility Criteria
* INCLUSION CRITERIA In order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Participant \>=18 years old 4. Has a specific diagnosis of a cardiopulmonary and/or vascular disease that puts them at risk of developing or having developed tissue fibrosis. 5. Has undergone prior imaging of lungs, heart, and/or vasculature with chest CT 6. Able to lie on the PET/CT scanner for imaging up to 45 minutes. 7. For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 4 weeks after the end of FAPI-PET/CT or the FDG PET/CT scan. 8. For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner during study participation and for an additional 4 weeks after the end of FAPI-PET/CT or the FDG PET/CT scan. 9. Ability of subject to understand and the willingness to sign a written informed consent document. EXCLUSION CRITERIA An individual who meets any of the following criteria will be excluded from participation in this study: 1. History of allergic reactions attributed to compounds of similar chemical or biologic composition to 18F-FAPI-74 or other agents used in the study. 2. Uncontrolled intercurrent illness, factors, or social situations that would limit compliance with study requirements 3. Pregnancy or lactation 4. Women able to become pregnant or men actively trying to father a child and are unwilling to use an effective form of birth control during the study and 4 weeks after the last 18F-FAPI-74 PET/CT scan or the FDG PET/CT scan. 5. Subjects with severe claustrophobia unresponsive to oral anxiolytics. 6. Subjects weighing \> 350 lbs (weight limit for PET scanner table), or unable to fit within the imaging gantry
Conditions Liver Cirrhosis, Clinically Significant ...
Phase NA
Enrollment 104
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

Liver transplantation is a procedure associated with an exceptionally high risk of blood loss. Liver failure, which is the most common indication for transplantation, not only leads to coagulation disorders but also to the development of portal hypertension. As a result, collateral circulation forms within the abdominal venous system, significantly increasing the risk of massive intraoperative blood loss. The number of intraoperatively transfused units of red blood cell concentrate is one of the main predictors of serious complications and postoperative mortality. Patients with portal hypertension awaiting liver transplantation should be treated with non-selective β-blockers, which reduce pressure in the portal system. This is primarily justified by the need to prevent esophageal variceal bleeding, one of the most common causes of decompensation in chronic liver failure and a potential cause of death while awaiting liver transplantation. According to the Baveno VII guidelines, if bleeding recurs despite the use of non-selective β-blockers, a transjugular intrahepatic portosystemic shunt (TIPS) should be considered. Significant reduction of portal pressure is observed in up to 50% of patients treated with propranolol and up to 75% with carvedilol. TIPS effectively prevents bleeding caused by portal hypertension. However, recommendations for pre-transplant management of portal hypertension do not address the reduction of blood loss risk during liver transplantation. Previous studies evaluating the use of TIPS before transplantation primarily confirmed its safety and showed no significant increase in intraoperative risk. One analysis even suggested using TIPS in all patients with portal hypertension awaiting liver transplantation. Although some studies have addressed the issue of blood loss during transplantation, they were observational and retrospective, without distinguishing patients at particularly high risk of massive blood loss. So far, the effectiveness of TIPS in reducing blood loss during liver transplantation has not been confirmed-nor have studies reliably excluded such potential. The objective of the study is to directly compare the effectiveness of two different methods of modulating portal hypertension in the context of the risk of massive blood loss during liver transplantation. We hypothesize that the superior effectiveness of TIPS in significantly reducing portal hypertension may lead to a significant decrease in blood loss and the need for transfusion of blood products in patients at high risk of massive blood loss.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Double

Interventions / Regimen

  • Procedure: Transjugular Intrahepatic Portosystemic Shunt — Transjugular Intrahepatic Portosystemic Shunt performed prior to liver transplantation in patients with increased risk of intraoperative blood loss
  • Drug: Non-selective beta-blockers — Non-selective beta-blockers for lowering portal hypertension

Primary Outcomes

  • Number of red blood cell units transfused during liver transplantation. (Intraoperative)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-06-24
Completion: 2029-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 104 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medical University of Warsaw
Collaborators: Medical Research Agency, Poland
Contact Information
Study Contact:
Wacław Hołówko, dr hab. n. med.
+48 667 667 044
waclaw.holowko@wum.edu.pl
Zuzanna Łuczak
luczakpresite@gmail.com
Wacław Hołówko, dr hab. n. med.
+48 667 667 044
waclaw.holowko@wum.edu.pl
University Clinical Centre of the Medical University of Warsaw
Interventions
  • Procedure: Transjugular Intrahepatic Portosystemic Shunt — Transjugular Intrahepatic Portosystemic Shunt performed prior to liver transplantation in patients with increased risk of intraoperative blood loss
  • Drug: Non-selective beta-blockers — Non-selective beta-blockers for lowering portal hypertension
Study Locations (1 sites)
University Clinical Centre of the Medical University of Warsaw, Warsaw, Poland
Eligibility Criteria
Inclusion Criteria: * Qualification for elective liver transplantation from a deceased donor * Age ≥18 years * BMI between 18.5 kg/m² and 30 kg/m² * Informed consent to participate in the study * Clinically significant portal hypertension * At least 1 of the following risk factors for massive blood loss: * Re-transplantation * Previous surgery in the upper abdomen * History of esophageal variceal bleeding * History of spontaneous bacterial peritonitis * Planned thrombectomy during liver transplantation Exclusion Criteria: * Heart failure (EF \<50%) * Severe right ventricular failure * Severe pulmonary hypertension * Systemic infection * Portal vein thrombosis (Yerdel \>1) * Severe coagulopathy (INR \>5) * Thrombocytopenia \<20,000/ml * Severe or uncontrolled encephalopathy (ammonia concentration \>100 μmol/l) * Contraindication to TIPS * Contraindication to therapy with non-selective beta-blockers * Pregnancy * Lack of informed consent to participate in the study
Conditions Metastatic Breast Cancer
Phase Not Applicable
Enrollment 150
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to assess the effectiveness of the mDETECT breast cancer blood test at monitoring treatment response in women with metastatic breast cancer undergoing treatment.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Change in ctDNA level from baseline to 6 months of treatment (Baseline - 6 months)
  • Changes in radiographic tumour assessments for monitoring response to treatment (3 months and 6 months)
  • Change in measurable lytic lesions in participants with bone only metastasis assessed by CT scans as measured per RECIST v.1.1 (3 months and 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-10-19
Completion: 2026-04
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Dr. Christopher Mueller
Collaborators: Canadian Institutes of Health Research (CIHR), Queen's University
Principal Investigators:
  • Christopher R Mueller, Ph.D. (PRINCIPAL_INVESTIGATOR) - Queen's University
Contact Information
Study Contact:
Christopher R Mueller, Ph.D.
613-533-6751
muellerc@queensu.ca
Keira Frosst
613-533-6773
16kmf4@queensu.ca
Brooke Wilson, MBBS, MSc, FRACP
(613) 548-3232
brooke.wilson@kingstonhsc.ca
Kingston Health Sciences Centre - Cancer Centre of Southeastern Ontario
Interventions
N/A
Study Locations (2 sites)
Kingston Health Sciences Centre - Cancer Centre of Southeastern Ontario, Kingston, Ontario K7L 5P9 Canada
Sunnybrook Health Sciences Centre, Toronto, Ontario M4N 3M5 Canada
Eligibility Criteria
Inclusion Criteria -Adult women (≥ 18 years of age) with proven diagnosis of adenocarcinoma of the breast with evidence of recurrent or metastatic disease not amenable to resection or radiation therapy with curative intent \[to be herein described as 'metastatic'\]
Conditions Benign Breast Lesions, Malignant Breast ...
Phase PHASE2
Enrollment 180
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this study is to evaluate the negative predictive value of the Photo Acoustic Imager 3+ (PAM3+) in the detection of female breast lesions (malignant and benign)in an outpatient setting.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Device: Photo-Acoustic Mammoscope Imager 3+ — Patients will lay in prone position on the PAM3+ with one breast at a time in the aperture of the machine. The breast is supported by a plastic cup that holds the breast in place. The aperture/bowl is filled with water. During the measurement, infrared light will be emitted onto the breast. Infrared light will be absorpted by red blood cells which results in contrast compared to its surroundings and it will cause minuscule movements in the surrounding water. These movements will be detected by the ultrasound detectors. The movements and the absorption together will create a 3D image of the breast.

Primary Outcomes

  • PAM3+ performance (through study completion, an average of 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-02-01
Completion: 2028-04-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 180 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Franciscus Gasthuis & Vlietland (Hospital)
Principal Investigators:
  • T.M.A.L. Klem, MD, PhD (PRINCIPAL_INVESTIGATOR) - Franciscus Gasthuis & Vlietland
Contact Information
Study Contact:
Linda Riks, MD
010 - 893 6010
l.riks@franciscus.nl
Linda Riks, MD
010 - 893 6010
l.riks@franciscus.nl
Franciscus Vlietland Ziekenhuis
Linda Riks, MD
Franciscus Vlietland Ziekenhuis
Interventions
  • Device: Photo-Acoustic Mammoscope Imager 3+ — Patients will lay in prone position on the PAM3+ with one breast at a time in the aperture of the machine. The breast is supported by a plastic cup that holds the breast in place. The aperture/bowl is filled with water. During the measurement, infrared light will be emitted onto the breast. Infrared light will be absorpted by red blood cells which results in contrast compared to its surroundings and it will cause minuscule movements in the surrounding water. These movements will be detected by the ultrasound detectors. The movements and the absorption together will create a 3D image of the breast.
Study Locations (1 sites)
Franciscus Vlietland Ziekenhuis, Schiedam, South Holland 3118 JH Netherlands
Eligibility Criteria
Inclusion Criteria: 1. Women 2. Age \> 18 years 3. Referred to the outpatient breast clinic of the Franciscus Vlietland Hospital due to a possible breast lesion 4. Patients who are fully competent to give written informed consent 5. Sufficient knowledge of the Dutch language to complete a questionnaire Exclusion Criteria: 1. Currently undergoing chemotherapy 2. Discharge from the nipple(s) 3. Breast ulcers or -wounds 4. Currently suffering from mastitis 5. Carrier of a resistant bacterium (e.g. Methicillin-resistant Staphylococcus aureus (MRSA) or Multidrug resistant organisms (MDRO; in Dutch: BRMO) 6. Irremovable piercings on/in the breast 7. Pregnancy 8. Patients whose breasts do not fit in the cup sizes (small breasts can be measured without a cup) 9. Currently using medication that increases photo-toxicity of the skin or skin care products that increase photosensitivity (e.g. certain antibiotics: tetracyclines or quinolones, certain antidiuretics 10. A history of photosensitive disease (e.g. porphyria, lupus erythematosus) 11. Currently undergoing therapy for a photosensitive disease and experiencing photosensitive disease 12. Currently undergoing phototherapy 13. Patients with a known allergy for PVC 14. Patients that are not physically capable of climbing on the examination bed 15. Patients that are not physically capable of laying on the examination bed during the measurements